Tavo Biotherapeutics Announces Appointment of Seasoned Executives to Key Posts
---- Lukas Scheibler, Ph.D. to become Chief Research and Development Officer and Graham Cooper to become Chief Financial Officer
---- Additions to senior team will drive Tavo's strategy to develop new innovative therapeutics addressing critical unmet needs in glaucoma and retinal disease
IRVINE, Calif. , April 29, 2025 /PRNewswire/ -- Tavo Biotherapeutics, a leading innovator in the ophthalmology industry, today announced the appointment of Lukas Scheibler, Ph.D. as Chief Research and Development Officer, and Graham Cooper as Chief Financial Officer. Both bring proven track records of success in the biotechnology industry.
'I am thrilled to bring on Lukas and Graham to Tavo's senior team,' said Gary Berman, Chief Executive Officer. 'Lukas has had an illustrious career in ophthalmology, from introducing Lucentis in Europe for Novartis, running clinical development at Alcon, and pioneering the development of Syfovre for geographic atrophy at Apellis. He is a recognized leader in the industry, and he will play a central role in driving our clinical and pre-clinical programs in treatments for glaucoma and retinal disease.'
Berman continued, 'Likewise, Graham has extensive experience in the biotech field, across multiple therapeutic indications. Throughout his career he has raised over a billion dollars in capital, having taken companies public and scaled enterprises from the early stages, hiring teams and managing growth. He is a recognized leader in the venture capital and public investor communities and brings a wealth of experience and strong relationships to Tavo. Lukas and Graham fill pivotal roles for Tavo, and they join us at a key time as we prepare to raise capital and advance our pipeline into the clinic. Attracting these accomplished executives builds on our momentum in developing breakthrough therapies that address fundamental unmet needs in ophthalmology.'
Dr. Lukas Scheibler was most recently Chief Innovation Officer at Apellis. In this role, he was responsible for all research and development activities through human proof of concept. Prior to that, he was Head of Clinical Development at Alcon, where he was responsible for the planning and execution of all clinical trials. Dr. Scheibler began his career in ophthalmology in research and development at Novartis, where he played a key role in the in-licensing and approval of Lucentis in Europe. He holds a Ph.D. from the University of Lausanne, Switzerland, and completed postdoctoral training at Harvard Medical School.
Graham Cooper was Chief Financial Officer for Receptos, which he joined prior to its IPO. At Receptos, he played a key role in managing through a dramatic growth phase and raising capital, culminating in its sale to Celgene for $7.8 billion. He also served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, developing innovative anti-viral therapies for the treatment of HBV, as well as other private and public biotechnology companies. Prior to his operating roles, Mr. Cooper held positions of increasing responsibility at Deutsche Bank Securities, including Director, Health Care Investment Banking. He began his career at Deloitte & Touche and was previously a CPA. Mr. Cooper currently serves as a member of the board of Beam Therapeutics (BEAM) and chairman of the board of Kezar Life Sciences (KZR). Mr. Cooper received a BA in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.
About Tavo Biotherapeutics
Tavo Biotherapeutics is developing innovative new treatments to address critical unmet needs in ophthalmology. TAV-001 is being developed for the treatment of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown substantial reduction in intraocular pressure, as well as signals of neuroprotection, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic macular edema and diabetic retinopathy, as well as both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program.
Media Contact:
Graham Cooper
Chief Financial Officer
[email protected]
www.tavobio.com
View original content: https://www.prnewswire.com/news-releases/tavo-biotherapeutics-announces-appointment-of-seasoned-executives-to-key-posts-302441252.html
SOURCE Tavo Biotherapeutics
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Shares of Novartis (NVS) have been strong performers lately, with the stock up 11.4% over the past month. The stock hit a new 52-week high of $120.92 in the previous session. Novartis has gained 24.1% since the start of the year compared to the -1.5% move for the Zacks Medical sector and the 2.8% return for the Zacks Large Cap Pharmaceuticals industry. The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on April 29, 2025, Novartis reported EPS of $2.28 versus consensus estimate of $2.12 while it beat the consensus revenue estimate by 2.88%. For the current fiscal year, Novartis is expected to post earnings of $8.74 per share on $54.29 billion in revenues. This represents a 11.91% change in EPS on a 7.13% change in revenues. For the next fiscal year, the company is expected to earn $9.02 per share on $55.2 billion in revenues. This represents a year-over-year change of 3.24% and 1.68%, respectively. Novartis may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level. On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style. Novartis has a Value Score of B. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of A. In terms of its value breakdown, the stock currently trades at 13.8X current fiscal year EPS estimates, which is not in-line with the peer industry average of 14.1X. On a trailing cash flow basis, the stock currently trades at 11.3X versus its peer group's average of 11.3X. Additionally, the stock has a PEG ratio of 1.75. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective. We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Novartis currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Novartis meets the list of requirements. Thus, it seems as though Novartis shares could have potential in the weeks and months to come. Shares of NVS have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Pfizer Inc. (PFE). PFE has a Zacks Rank of # 2 (Buy) and a Value Score of A, a Growth Score of C, and a Momentum Score of F. Earnings were strong last quarter. Pfizer Inc. beat our consensus estimate by 43.75%, and for the current fiscal year, PFE is expected to post earnings of $3.06 per share on revenue of $63.25 billion. Shares of Pfizer Inc. have gained 9.9% over the past month, and currently trade at a forward P/E of 8.11X and a P/CF of 5.69X. The Large Cap Pharmaceuticals industry is in the top 16% of all the industries we have in our universe, so it looks like there are some nice tailwinds for NVS and PFE, even beyond their own solid fundamental situation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Shares of Novartis (NVS) have been strong performers lately, with the stock up 11.4% over the past month. The stock hit a new 52-week high of $120.92 in the previous session. Novartis has gained 24.1% since the start of the year compared to the -1.5% move for the Zacks Medical sector and the 2.8% return for the Zacks Large Cap Pharmaceuticals industry. The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on April 29, 2025, Novartis reported EPS of $2.28 versus consensus estimate of $2.12 while it beat the consensus revenue estimate by 2.88%. For the current fiscal year, Novartis is expected to post earnings of $8.74 per share on $54.29 billion in revenues. This represents a 11.91% change in EPS on a 7.13% change in revenues. For the next fiscal year, the company is expected to earn $9.02 per share on $55.2 billion in revenues. This represents a year-over-year change of 3.24% and 1.68%, respectively. Novartis may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level. On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style. Novartis has a Value Score of B. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of A. In terms of its value breakdown, the stock currently trades at 13.8X current fiscal year EPS estimates, which is not in-line with the peer industry average of 14.1X. On a trailing cash flow basis, the stock currently trades at 11.3X versus its peer group's average of 11.3X. Additionally, the stock has a PEG ratio of 1.75. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective. We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Novartis currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Novartis meets the list of requirements. Thus, it seems as though Novartis shares could have potential in the weeks and months to come. Shares of NVS have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Pfizer Inc. (PFE). PFE has a Zacks Rank of # 2 (Buy) and a Value Score of A, a Growth Score of C, and a Momentum Score of F. Earnings were strong last quarter. Pfizer Inc. beat our consensus estimate by 43.75%, and for the current fiscal year, PFE is expected to post earnings of $3.06 per share on revenue of $63.25 billion. Shares of Pfizer Inc. have gained 9.9% over the past month, and currently trade at a forward P/E of 8.11X and a P/CF of 5.69X. The Large Cap Pharmaceuticals industry is in the top 16% of all the industries we have in our universe, so it looks like there are some nice tailwinds for NVS and PFE, even beyond their own solid fundamental situation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Novartis reports positive results from Phase IIIB study of iptacopan for PNH
Novartis has reported positive outcomes from the multi-centre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan) in adults with paroxysmal nocturnal haemoglobinuria (PNH). These findings are set to be presented at the European Hematology Association (EHA) Congress in 2025. The single-arm, open-label, multinational trial assessed the oral therapy in PNH subjects with haemoglobin (Hb) levels of ≥10g/dL, who transitioned from anti-C5 therapies (eculizumab or ravulizumab). It enrolled 52 subjects and aimed to expand the clinical evidence for the therapy by including patients with higher baseline Hb levels than those in the pivotal Phase III programme. Following 24 weeks of treatment with the therapy, subjects experienced an average increase in Hb levels of 2.01g/dL, with a significant number achieving normal or near-normal levels. During the trial, none of the participants needed blood transfusions, and 92.7% of them reached Hb levels of at least 12g/dL. In addition, subjects reported improvements in fatigue, with Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scores aligning with those of the general population by day 168. Novartis noted that Fabhalta-treated subjects also maintained intravascular haemolysis control and resolved extravascular haemolysis control, indicated by lactate dehydrogenase levels remaining below 1.5 times the upper limit of normal and a decrease in absolute reticulocyte count. Along with these findings, the company will also present longer-term data from the APPLY-PNH and APPOINT-PNH Phase III trials at the EHA Congress. Novartis development president and chief medical officer Shreeram Aradhye said: 'New data from APPULSE-PNH, combined with findings from the Phase III roll-over extension of the APPLY-PNH and APPOINT-PNH studies, reinforce the efficacy and safety profile of Fabhalta in delivering real benefits to patients.' Fabhalta was discovered by Novartis and acts as a Factor B inhibitor of the alternative complement pathway. It also offers a new treatment option for the rare and life-threatening complement-mediated blood disorder, PNH. The company recently shared topline outcomes from the Phase III PSMAddition trial's pre-specified interim analysis, in which Pluvicto plus standard of care (SoC) treatment demonstrated a benefit in treating prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). "Novartis reports positive results from Phase IIIB study of iptacopan for PNH" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
